• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Giiant Pharma raises $11M for drug delivery platform for gastroenterology

May 21, 2021 By Sean Whooley

GIIANT Pharma_Logo_RGB_nonameGiiant Pharma announced today that it closed a $11 million seed financing round for its drug delivery technology platform.

Montreal-based Giiant develops the Precision Delivery technology platform, which originated from the work of former Merck Frosst scientists, according to a news release. The company designs gut-restricted, tissue-specific, small-molecule drug therapeutics to be delivered through the platform.

“Precision Delivery is an exciting concept which has the potential to transform the field of gastroenterology,” Giiant Pharma CEO Maxime Ranger said in the release.

The company identified the orally administered, colon-specific PDE4 inhibitor prodrug GT-2108 as a lead candidate for treating inflammatory bowel diseases (IBD). GT-2108 has potent anti-inflammatory properties and its prodrug format requires activation by the gut microbiota before the drug can elicit its effects, Giiant said.

With the $11 million in funds raised, Giiant initiated the investigational new drug-enabling preclinical program with GT-2108 for treating moderate-to-severe ulcerative colitis. The company is also discussing the potential expansion of its pipeline for treating gastrointestinal disease.

“With a unique ability to deliver an active PDE4 inhibitor to the site of inflammation in the gut, we expect limited systemic exposure and a safer profile,” Giiant Pharma co-founder & chief development officer Dr. Elizabeth Kwong said.

Funds in the seed round came from co-leaders Amplitude Ventures and Genesys Capital, while Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec and other angel investors contributed.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Preclinical Trials Tagged With: Giiant Pharma

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS